Skip to search formSkip to main contentSkip to account menu

celecoxib/exemestane

Known as: Celecoxib + Exemestane, PNU 155971/SC-58635 
National Institutes of Health

Related topics

Related topics

2 relations
celecoxibexemestane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC…
1005Background: BOLERO-6 (NCT01783444) was designed to estimate the clinical benefit of EVE + EXE vs EVE alone or CAP for ER… 
2017
2017
Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression…
Background: There is extensive crosstalk between the cyclin D–CDK4/6–inhibitor of CDK4–retinoblastoma and phosphatidylinositol 3… 
2012
2012
BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.
125 Background: BOLERO-2, a phase III study, randomized 724 patients with hormone-receptor–positive metastatic breast cancer, who… 
2012
2012
BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.
125 Background: BOLERO-2, a phase III study, randomized 724 patients with hormone-receptor-positive metastatic breast cancer, who… 
2007
2007
P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)